Compile Data Set for Download or QSAR
Report error Found 42 Enz. Inhib. hit(s) with all data for entry = 1581
TargetEpidermal growth factor receptor(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM5446(Erlotinib | OSI-774 | N-(3-ethynylphenyl)-6,7-bis(...)
Affinity DataIC50: 1.20nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetEpidermal growth factor receptor(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50069096(CHEMBL3403517 | US10189853, Compound 10)
Affinity DataIC50: 3.40nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM331862(US10189853, Compound 7)
Affinity DataIC50: 5.80nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM331860(US10189853, Compound 6)
Affinity DataIC50: 6.70nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM4810(cid_5329098 | CHEMBL276711 | SU5146 | (3Z)-3-[(3,5...)
Affinity DataIC50: 12.9nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50069102(CHEMBL3403510 | US10189853, Compound 3)
Affinity DataIC50: 18.6nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM158478(US9029401, Sunitinib | US9695181, Sunitinib | US10...)
Affinity DataIC50: 18.9nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50022542(CHEMBL3297898 | US10189853, Compound 1)
Affinity DataIC50: 19.1nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50069100(CHEMBL3403512 | US10189853, Compound 5)
Affinity DataIC50: 19.9nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM331864(US10189853, Compound 8)
Affinity DataIC50: 20.9nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor alpha(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50022542(CHEMBL3297898 | US10189853, Compound 1)
Affinity DataIC50: 22.8nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor alpha(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM331860(US10189853, Compound 6)
Affinity DataIC50: 24.6nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor alpha(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM331862(US10189853, Compound 7)
Affinity DataIC50: 25nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50069103(CHEMBL3403509 | US10189853, Compound 2)
Affinity DataIC50: 32.3nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50069096(CHEMBL3403517 | US10189853, Compound 10)
Affinity DataIC50: 33.2nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50069097(CHEMBL3403518 | US10189853, Compound 11)
Affinity DataIC50: 38.5nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor alpha(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50069103(CHEMBL3403509 | US10189853, Compound 2)
Affinity DataIC50: 40.4nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor alpha(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50069100(CHEMBL3403512 | US10189853, Compound 5)
Affinity DataIC50: 50.1nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor alpha(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50069096(CHEMBL3403517 | US10189853, Compound 10)
Affinity DataIC50: 58.2nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor alpha(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50069102(CHEMBL3403510 | US10189853, Compound 3)
Affinity DataIC50: 66.1nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50022542(CHEMBL3297898 | US10189853, Compound 1)
Affinity DataIC50: 68.2nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor alpha(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM331864(US10189853, Compound 8)
Affinity DataIC50: 73.2nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor alpha(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM158478(US9029401, Sunitinib | US9695181, Sunitinib | US10...)
Affinity DataIC50: 83.1nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor alpha(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50069097(CHEMBL3403518 | US10189853, Compound 11)
Affinity DataIC50: 84nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50069102(CHEMBL3403510 | US10189853, Compound 3)
Affinity DataIC50: 90.3nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50069097(CHEMBL3403518 | US10189853, Compound 11)
Affinity DataIC50: 102nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM331864(US10189853, Compound 8)
Affinity DataIC50: 103nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50069098(CHEMBL3403519 | US10189853, Compound 12)
Affinity DataIC50: 121nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM5446(Erlotinib | OSI-774 | N-(3-ethynylphenyl)-6,7-bis(...)
Affinity DataIC50: 125nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor alpha(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50069098(CHEMBL3403519 | US10189853, Compound 12)
Affinity DataIC50: 132nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50069103(CHEMBL3403509 | US10189853, Compound 2)
Affinity DataIC50: 162nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor alpha(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50069101(CHEMBL3403511 | US10189853, Compound 4)
Affinity DataIC50: 166nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM158478(US9029401, Sunitinib | US9695181, Sunitinib | US10...)
Affinity DataIC50: 172nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor alpha(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50069095(CHEMBL3403516 | US10189853, Compound 9)
Affinity DataIC50: 198nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM331860(US10189853, Compound 6)
Affinity DataIC50: 226nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50069100(CHEMBL3403512 | US10189853, Compound 5)
Affinity DataIC50: 298nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50069095(CHEMBL3403516 | US10189853, Compound 9)
Affinity DataIC50: 300nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50069101(CHEMBL3403511 | US10189853, Compound 4)
Affinity DataIC50: 300nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM331862(US10189853, Compound 7)
Affinity DataIC50: 307nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50069095(CHEMBL3403516 | US10189853, Compound 9)
Affinity DataIC50: 500nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50069098(CHEMBL3403519 | US10189853, Compound 12)
Affinity DataIC50: 500nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50069101(CHEMBL3403511 | US10189853, Compound 4)
Affinity DataIC50: 500nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent